Research background · Updated November 1, 2026
CJC-1295 with DAC Research: Publications, Study Types and Background
Short answer
CJC-1295 with DAC. As of November 1, 2026, PubMed indexes 2 records matching CJC-1295 with DAC, the earliest from 2026; 0 were published in 2021–2025 and 1 are reviews. ClinicalTrials.gov lists 0 registered studies matching the compound.
- PubMed records
- 2
- Earliest record
- 2026
- Published 2021–2025
- 0
- Reviews
- 1
- Animal-only studies
- 0
- Registered studies
- 0
Publications per year, 2006–2025
0 records in 2016–2025 against 0 in 2006–2015.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 0 |
| 2022 | 0 |
| 2023 | 0 |
| 2024 | 0 |
| 2025 | 0 |
Study types
| All PubMed records | 2 |
|---|---|
| Reviews | 150% |
| Animal studies (no human subjects indexed) | 00% |
| Indexed as clinical trials | 00% |
| Registered on ClinicalTrials.gov | 0 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 2 of the most-cited and most recent CJC-1295 with DAC papers report, in their own authors’ terms. Each line links the paper it came from.
Growth hormone and IGF-I secretion, and half-life
In a randomized trial in healthy adults, a single CJC-1295 injection raised mean plasma growth hormone 2- to 10-fold for six days or more and mean plasma IGF-I 1.5- to 3-fold for 9 to 11 days; the estimated half-life of CJC-1295 was 5.8 to 8.1 days.
HumansTeichman SL 2006The Journal of clinical endocrinology and metabolismPMID 16352683
Serum biomarkers of growth hormone action
In serum collected from healthy adults before and one week after a CJC-1295 injection, the authors used two-dimensional gel electrophoresis and mass spectrometry to look for proteins that change with growth hormone and IGF-1 activity, and tested whether they correlated with GH and IGF-1 levels.
HumansSackmann-Sala L 2009Growth hormone & IGF researchPMID 19386527
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 2 of the 2 records. They describe what the literature is about, not what CJC-1295 with DAC does.
- Insulin-Like Growth Factor I1 papers
- Performance-Enhancing Substances1 papers
- Human Growth Hormone1 papers
Key papers
Earliest indexed record
Dominikowski A (2026). Frontiers in endocrinology.
PMID 42395176
Citation counts from NIH iCite, among the 2 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| CAS | 446262-90-4 |
|---|---|
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647.2 g/mol |
| Synonyms | CJC 1295, CJC-1295, 62RC32V9N7, DTXSID501027567, CJC1295 |
Identity data from PubChem, retrieved November 1, 2026, on the CJC-1295 with DAC page.
How these numbers were counted
- PubMed search, run November 1, 2026:
("CJC-1295"[tiab] OR "CJC 1295"[tiab]) AND (DAC[tiab] OR "drug affinity complex"[tiab])re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"CJC-1295" AND DACre-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use CJC-1295 with DAC outside a laboratory.
Wholesale supply
CJC-1295 with DAC, sourced to order for research.
Not held in the listed catalog. Tell us the vial size and the number of vials and we come back with availability, documentation and pricing in writing.
CJC-1295 with DAC research questions
How much research has been published on CJC-1295 with DAC?
PubMed indexes 2 records matching CJC-1295 with DAC (searched November 1, 2026), including 1 reviews and 0 records indexed as clinical trials. 0 were published in the five years 2021–2025.
When was CJC-1295 with DAC first described in the literature?
The earliest PubMed record matching CJC-1295 with DAC is from 2026 (Dominikowski A, Frontiers in endocrinology, PMID 42395176).
What topics does the CJC-1295 with DAC literature cover?
The subject headings PubMed indexers most often marked as a main topic of CJC-1295 with DAC papers are Insulin-Like Growth Factor I, Performance-Enhancing Substances, Human Growth Hormone. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is CJC-1295 with DAC sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy CJC-1295 with DAC wholesale for research?
We source CJC-1295 with DAC to order rather than stock it. Tell us the vial size and number of vials on WhatsApp or by email and the quote confirms availability, documentation and pricing.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.